Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-10

AUTHORS

Amit Garg, Angelica Quartino, Jing Li, Jin Jin, D. Russell Wada, Hanbin Li, Javier Cortés, Virginia McNally, Graham Ross, Jennifer Visich, Bert Lum

ABSTRACT

PURPOSE: To characterize the population pharmacokinetics (PK) of pertuzumab across clinical trials in a variety of solid tumors, evaluate the potential impact of patient characteristics on PK, and confirm the appropriateness of the fixed (non-weight-based) dose. METHODS: Pertuzumab concentration data collected following intravenous administration during eleven phase I/II studies and the pivotal phase III trial CLEOPATRA were analyzed using nonlinear mixed-effects modeling. The potential impact of patient and laboratory characteristics and HER2 target-related variables on pertuzumab PK were investigated in a covariate analysis. The final model was used to confirm selection of fixed, non-weight-based dosing of pertuzumab, and to compare pertuzumab PK in CLEOPATRA with the other studies. RESULTS: The analysis included 4,525 serum concentration measurements from 481 patients with solid tumors. Pertuzumab PK in the 2-25 mg/kg dose range was described by a two-compartment linear model with first-order elimination. The elimination clearance and central compartment volume were 0.235 L/day, and 3.11 L, respectively, and the terminal elimination half-life was 18.0 days. Baseline serum albumin and lean body weight had statistically significant effects on pertuzumab clearance; however, simulations showed that the magnitude of their effects on pertuzumab exposure was minimal compared with overall variability and was not clinically relevant. Thus, variations in these factors do not require dose adjustments. CONCLUSIONS: The fixed, non-weight-based dosing of pertuzumab, 840 mg loading dose followed by a 420 mg maintenance dose every 3 weeks, in patients with the solid tumors in this analysis is well supported by the population pharmacokinetic modeling and simulation results. More... »

PAGES

819-829

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-014-2560-3

DOI

http://dx.doi.org/10.1007/s00280-014-2560-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004783955

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25119184


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Weight", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Decision Support Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, erbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Clearance Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nonlinear Dynamics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serum Albumin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Clinical Pharmacology, MS 463a, Genentech, Inc., 1 DNA Way, 94080, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garg", 
        "givenName": "Amit", 
        "id": "sg:person.01156553111.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156553111.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Clinical Pharmacology, MS 463a, Genentech, Inc., 1 DNA Way, 94080, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quartino", 
        "givenName": "Angelica", 
        "id": "sg:person.01320560307.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320560307.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Clinical Pharmacology, MS 463a, Genentech, Inc., 1 DNA Way, 94080, South San Francisco, CA, USA", 
            "MedImmune, 24500 Clawiter Road, 94545, Hayward, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Jing", 
        "id": "sg:person.013666353540.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013666353540.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Clinical Pharmacology, MS 463a, Genentech, Inc., 1 DNA Way, 94080, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jin", 
        "givenName": "Jin", 
        "id": "sg:person.016026247332.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016026247332.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Quantitative Solutions Inc., 94025, Menlo Park, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wada", 
        "givenName": "D. Russell", 
        "id": "sg:person.01274422554.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274422554.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Quantitative Solutions Inc., 94025, Menlo Park, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Hanbin", 
        "id": "sg:person.01034251740.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034251740.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitari Vall d'Hebron", 
          "id": "https://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Department of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cort\u00e9s", 
        "givenName": "Javier", 
        "id": "sg:person.015330562112.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015330562112.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "F. Hoffmann-La Roche Ltd, 6 Falcon Way, Shire Park, Hexagon Place, AL7 1TW, Welwyn Garden City, Hertfordshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McNally", 
        "givenName": "Virginia", 
        "id": "sg:person.0740256140.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740256140.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "F. Hoffmann-La Roche Ltd, 6 Falcon Way, Shire Park, Hexagon Place, AL7 1TW, Welwyn Garden City, Hertfordshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ross", 
        "givenName": "Graham", 
        "id": "sg:person.0630377443.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630377443.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Clinical Pharmacology, MS 463a, Genentech, Inc., 1 DNA Way, 94080, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Visich", 
        "givenName": "Jennifer", 
        "id": "sg:person.01246121610.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246121610.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Clinical Pharmacology, MS 463a, Genentech, Inc., 1 DNA Way, 94080, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lum", 
        "givenName": "Bert", 
        "id": "sg:person.0716757142.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716757142.45"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01061469", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000869925", 
          "https://doi.org/10.1007/bf01061469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt201.21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000974569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.24.2024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001727306"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(04)00083-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002635571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clim.2006.09.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002784837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11596370-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002877462", 
          "https://doi.org/10.2165/11596370-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11596370-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002877462", 
          "https://doi.org/10.2165/11596370-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270009337512", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002934176"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cllc.2012.03.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003176650"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003642271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70336-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006777850"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jjco/hyp006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008373070"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(02)00097-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009224253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.22.3354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009371322"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-4636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010128696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1113216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013126608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70130-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014610655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.07.0888", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.37.4207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019059111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.05.4221", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019457020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.24.1661", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028339567"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030996000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030996000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11531280-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033453107", 
          "https://doi.org/10.2165/11531280-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11531280-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033453107", 
          "https://doi.org/10.2165/11531280-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604043", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033972314", 
          "https://doi.org/10.1038/sj.bjc.6604043"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-1026-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034184349", 
          "https://doi.org/10.1007/s00280-005-1026-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-1026-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034184349", 
          "https://doi.org/10.1007/s00280-005-1026-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.07.0649", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042521222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature01392", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044473219", 
          "https://doi.org/10.1038/nature01392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12248-009-9133-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046129728", 
          "https://doi.org/10.1208/s12248-009-9133-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajpgi.00286.2005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046893737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr2891", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048134520", 
          "https://doi.org/10.1186/bcr2891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-1980", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048629373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2009.03.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048708034"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049729330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-0460", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050562687"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds282", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052126620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270009339192", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053425807"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-08-4597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053676255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11095-006-0205-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053700895", 
          "https://doi.org/10.1007/s11095-006-0205-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cpp48297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072835721"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077362565", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-10", 
    "datePublishedReg": "2014-10-01", 
    "description": "PURPOSE: To characterize the population pharmacokinetics (PK) of pertuzumab across clinical trials in a variety of solid tumors, evaluate the potential impact of patient characteristics on PK, and confirm the appropriateness of the fixed (non-weight-based) dose.\nMETHODS: Pertuzumab concentration data collected following intravenous administration during eleven phase I/II studies and the pivotal phase III trial CLEOPATRA were analyzed using nonlinear mixed-effects modeling. The potential impact of patient and laboratory characteristics and HER2 target-related variables on pertuzumab PK were investigated in a covariate analysis. The final model was used to confirm selection of fixed, non-weight-based dosing of pertuzumab, and to compare pertuzumab PK in CLEOPATRA with the other studies.\nRESULTS: The analysis included 4,525 serum concentration measurements from 481 patients with solid tumors. Pertuzumab PK in the 2-25 mg/kg dose range was described by a two-compartment linear model with first-order elimination. The elimination clearance and central compartment volume were 0.235 L/day, and 3.11 L, respectively, and the terminal elimination half-life was 18.0 days. Baseline serum albumin and lean body weight had statistically significant effects on pertuzumab clearance; however, simulations showed that the magnitude of their effects on pertuzumab exposure was minimal compared with overall variability and was not clinically relevant. Thus, variations in these factors do not require dose adjustments.\nCONCLUSIONS: The fixed, non-weight-based dosing of pertuzumab, 840 mg loading dose followed by a 420 mg maintenance dose every 3 weeks, in patients with the solid tumors in this analysis is well supported by the population pharmacokinetic modeling and simulation results.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-014-2560-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "74"
      }
    ], 
    "name": "Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors", 
    "pagination": "819-829", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "16cb86b696e6620ca5cc9542c5c1e943a52c1ea6fa85f108fb42003facd5f5ae"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25119184"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-014-2560-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004783955"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-014-2560-3", 
      "https://app.dimensions.ai/details/publication/pub.1004783955"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000510.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-014-2560-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2560-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2560-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2560-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2560-3'


 

This table displays all metadata directly associated to this object as RDF triples.

344 TRIPLES      21 PREDICATES      85 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-014-2560-3 schema:about N230da7bd0c964d29b7d73c7f6a9f2cbd
2 N28e91963d2e14380b6231d5a4c9d4f1e
3 N2c494828dd474f749c7a5687670f3bba
4 N2c786f87a41d42548ae1dfc595e1d8eb
5 N3fc231d5bd724791a1a2a66a1b7b9a66
6 N52f68e50db824667928b7be0d4f498c4
7 N67a2bfbd1efe468ba241ebb03af9aaa4
8 N730463e4e4354df3816ecf68e30466f9
9 N79fcb6061d9846f9b68a5bb34754ad59
10 N805f9d0b4be449c596e69e8e11516e37
11 N884654f4ee514ed098d9aacbfcf4fd09
12 Nabf5a31760704c91959ce09604d6ba20
13 Nb624b9c34ff84cdd8d00d6d7feab7cfe
14 Nc55e973b346d480594d5cbfadfaaccc3
15 Nd5a3239f102e426dba48cfcf6e4889d1
16 Ndb3636e1a48d4ae8901f574cf07eb305
17 Nf506763ecba04f4f88e70c4d57dece29
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author Nda639900ce6e4ba59e5f2338ff9ba166
21 schema:citation sg:pub.10.1007/bf01061469
22 sg:pub.10.1007/s00280-005-1026-z
23 sg:pub.10.1007/s11095-006-0205-x
24 sg:pub.10.1038/nature01392
25 sg:pub.10.1038/sj.bjc.6604043
26 sg:pub.10.1186/bcr2891
27 sg:pub.10.1208/s12248-009-9133-0
28 sg:pub.10.2165/11531280-000000000-00000
29 sg:pub.10.2165/11596370-000000000-00000
30 https://app.dimensions.ai/details/publication/pub.1077362565
31 https://doi.org/10.1016/j.ccr.2009.03.020
32 https://doi.org/10.1016/j.clim.2006.09.001
33 https://doi.org/10.1016/j.cllc.2012.03.004
34 https://doi.org/10.1016/s1470-2045(11)70336-9
35 https://doi.org/10.1016/s1470-2045(13)70130-x
36 https://doi.org/10.1016/s1535-6108(02)00097-1
37 https://doi.org/10.1016/s1535-6108(04)00083-2
38 https://doi.org/10.1056/nejmoa1113216
39 https://doi.org/10.1093/annonc/mds282
40 https://doi.org/10.1093/annonc/mdt182
41 https://doi.org/10.1093/annonc/mdt201.21
42 https://doi.org/10.1093/jjco/hyp006
43 https://doi.org/10.1097/cad.0000000000000016
44 https://doi.org/10.1152/ajpgi.00286.2005
45 https://doi.org/10.1158/0008-5472.can-08-4597
46 https://doi.org/10.1158/1078-0432.ccr-07-0460
47 https://doi.org/10.1158/1078-0432.ccr-07-1980
48 https://doi.org/10.1158/1078-0432.ccr-07-4636
49 https://doi.org/10.1177/0091270009337512
50 https://doi.org/10.1177/0091270009339192
51 https://doi.org/10.1200/jco.2005.03.184
52 https://doi.org/10.1200/jco.2005.05.4221
53 https://doi.org/10.1200/jco.2006.07.0649
54 https://doi.org/10.1200/jco.2006.07.0888
55 https://doi.org/10.1200/jco.2009.22.3354
56 https://doi.org/10.1200/jco.2009.24.1661
57 https://doi.org/10.1200/jco.2009.24.2024
58 https://doi.org/10.1200/jco.2011.37.4207
59 https://doi.org/10.5414/cpp48297
60 schema:datePublished 2014-10
61 schema:datePublishedReg 2014-10-01
62 schema:description PURPOSE: To characterize the population pharmacokinetics (PK) of pertuzumab across clinical trials in a variety of solid tumors, evaluate the potential impact of patient characteristics on PK, and confirm the appropriateness of the fixed (non-weight-based) dose. METHODS: Pertuzumab concentration data collected following intravenous administration during eleven phase I/II studies and the pivotal phase III trial CLEOPATRA were analyzed using nonlinear mixed-effects modeling. The potential impact of patient and laboratory characteristics and HER2 target-related variables on pertuzumab PK were investigated in a covariate analysis. The final model was used to confirm selection of fixed, non-weight-based dosing of pertuzumab, and to compare pertuzumab PK in CLEOPATRA with the other studies. RESULTS: The analysis included 4,525 serum concentration measurements from 481 patients with solid tumors. Pertuzumab PK in the 2-25 mg/kg dose range was described by a two-compartment linear model with first-order elimination. The elimination clearance and central compartment volume were 0.235 L/day, and 3.11 L, respectively, and the terminal elimination half-life was 18.0 days. Baseline serum albumin and lean body weight had statistically significant effects on pertuzumab clearance; however, simulations showed that the magnitude of their effects on pertuzumab exposure was minimal compared with overall variability and was not clinically relevant. Thus, variations in these factors do not require dose adjustments. CONCLUSIONS: The fixed, non-weight-based dosing of pertuzumab, 840 mg loading dose followed by a 420 mg maintenance dose every 3 weeks, in patients with the solid tumors in this analysis is well supported by the population pharmacokinetic modeling and simulation results.
63 schema:genre research_article
64 schema:inLanguage en
65 schema:isAccessibleForFree false
66 schema:isPartOf N07bc2226f2764ac28262b58076f78c9b
67 N2b86282e87f140c1ad77b684d5750e33
68 sg:journal.1088364
69 schema:name Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors
70 schema:pagination 819-829
71 schema:productId N27c43775c34d4faca223eaf3cc4d1585
72 N6678e578c3924d4da5b19750f0df6dda
73 Nb4ecaf75b80244c9adfa3713d4b38df1
74 Ne8dae68bcb8e4097a1563973cde2273d
75 Nf4d64deeacb64f579df61041f3cd569e
76 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004783955
77 https://doi.org/10.1007/s00280-014-2560-3
78 schema:sdDatePublished 2019-04-10T20:46
79 schema:sdLicense https://scigraph.springernature.com/explorer/license/
80 schema:sdPublisher N6672dce43aab408d93e3111c62cb8123
81 schema:url http://link.springer.com/10.1007%2Fs00280-014-2560-3
82 sgo:license sg:explorer/license/
83 sgo:sdDataset articles
84 rdf:type schema:ScholarlyArticle
85 N07bc2226f2764ac28262b58076f78c9b schema:volumeNumber 74
86 rdf:type schema:PublicationVolume
87 N230da7bd0c964d29b7d73c7f6a9f2cbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Clinical Trials as Topic
89 rdf:type schema:DefinedTerm
90 N27c43775c34d4faca223eaf3cc4d1585 schema:name pubmed_id
91 schema:value 25119184
92 rdf:type schema:PropertyValue
93 N28e91963d2e14380b6231d5a4c9d4f1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Antibodies, Monoclonal, Humanized
95 rdf:type schema:DefinedTerm
96 N2b86282e87f140c1ad77b684d5750e33 schema:issueNumber 4
97 rdf:type schema:PublicationIssue
98 N2c494828dd474f749c7a5687670f3bba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Neoplasms
100 rdf:type schema:DefinedTerm
101 N2c786f87a41d42548ae1dfc595e1d8eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Female
103 rdf:type schema:DefinedTerm
104 N38ff251254694ac6a30b3d600251bed9 rdf:first sg:person.01246121610.06
105 rdf:rest N39baac0b941e484687ef2b6f236d30fa
106 N39baac0b941e484687ef2b6f236d30fa rdf:first sg:person.0716757142.45
107 rdf:rest rdf:nil
108 N3a0fde759829439aae23cb3bd27981ca rdf:first sg:person.01274422554.44
109 rdf:rest Nb7c0619b4eda4a458fffefbc774b0346
110 N3fc231d5bd724791a1a2a66a1b7b9a66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Male
112 rdf:type schema:DefinedTerm
113 N49fec7a46a564634a35e1e898f180830 schema:name Quantitative Solutions Inc., 94025, Menlo Park, CA, USA
114 rdf:type schema:Organization
115 N4cafb4e73cd24b10b5bc82e6418174dc schema:name F. Hoffmann-La Roche Ltd, 6 Falcon Way, Shire Park, Hexagon Place, AL7 1TW, Welwyn Garden City, Hertfordshire, UK
116 rdf:type schema:Organization
117 N52f68e50db824667928b7be0d4f498c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Nonlinear Dynamics
119 rdf:type schema:DefinedTerm
120 N55e390ae81cb4a2996bff971f6886220 rdf:first sg:person.013666353540.75
121 rdf:rest Ne9e4af4a472b439dbea1d6b885946439
122 N6672dce43aab408d93e3111c62cb8123 schema:name Springer Nature - SN SciGraph project
123 rdf:type schema:Organization
124 N6678e578c3924d4da5b19750f0df6dda schema:name nlm_unique_id
125 schema:value 7806519
126 rdf:type schema:PropertyValue
127 N67a2bfbd1efe468ba241ebb03af9aaa4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Antineoplastic Agents
129 rdf:type schema:DefinedTerm
130 N730463e4e4354df3816ecf68e30466f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Decision Support Techniques
132 rdf:type schema:DefinedTerm
133 N76475b9e0e5249bfba40824a75fd7a96 rdf:first sg:person.0630377443.79
134 rdf:rest N38ff251254694ac6a30b3d600251bed9
135 N79fcb6061d9846f9b68a5bb34754ad59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Infusions, Intravenous
137 rdf:type schema:DefinedTerm
138 N805f9d0b4be449c596e69e8e11516e37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Body Weight
140 rdf:type schema:DefinedTerm
141 N80c117f7b4454f83a73a167279262c19 rdf:first sg:person.015330562112.33
142 rdf:rest Ne47cfde5fba64f5681d396ffc641fb13
143 N884654f4ee514ed098d9aacbfcf4fd09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Dose-Response Relationship, Drug
145 rdf:type schema:DefinedTerm
146 Na5889b6c38c9449eac16dcf54c856cc8 rdf:first sg:person.01320560307.61
147 rdf:rest N55e390ae81cb4a2996bff971f6886220
148 Nabf5a31760704c91959ce09604d6ba20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Metabolic Clearance Rate
150 rdf:type schema:DefinedTerm
151 Nadd324ad84f840e2b24200823b73518f schema:name F. Hoffmann-La Roche Ltd, 6 Falcon Way, Shire Park, Hexagon Place, AL7 1TW, Welwyn Garden City, Hertfordshire, UK
152 rdf:type schema:Organization
153 Nb4ecaf75b80244c9adfa3713d4b38df1 schema:name readcube_id
154 schema:value 16cb86b696e6620ca5cc9542c5c1e943a52c1ea6fa85f108fb42003facd5f5ae
155 rdf:type schema:PropertyValue
156 Nb624b9c34ff84cdd8d00d6d7feab7cfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Serum Albumin
158 rdf:type schema:DefinedTerm
159 Nb7c0619b4eda4a458fffefbc774b0346 rdf:first sg:person.01034251740.93
160 rdf:rest N80c117f7b4454f83a73a167279262c19
161 Nc55e973b346d480594d5cbfadfaaccc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Genes, erbB-2
163 rdf:type schema:DefinedTerm
164 Nd5a3239f102e426dba48cfcf6e4889d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Humans
166 rdf:type schema:DefinedTerm
167 Nda639900ce6e4ba59e5f2338ff9ba166 rdf:first sg:person.01156553111.63
168 rdf:rest Na5889b6c38c9449eac16dcf54c856cc8
169 Ndb3636e1a48d4ae8901f574cf07eb305 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Half-Life
171 rdf:type schema:DefinedTerm
172 Ne47cfde5fba64f5681d396ffc641fb13 rdf:first sg:person.0740256140.14
173 rdf:rest N76475b9e0e5249bfba40824a75fd7a96
174 Ne8dae68bcb8e4097a1563973cde2273d schema:name doi
175 schema:value 10.1007/s00280-014-2560-3
176 rdf:type schema:PropertyValue
177 Ne9e4af4a472b439dbea1d6b885946439 rdf:first sg:person.016026247332.04
178 rdf:rest N3a0fde759829439aae23cb3bd27981ca
179 Nf4d64deeacb64f579df61041f3cd569e schema:name dimensions_id
180 schema:value pub.1004783955
181 rdf:type schema:PropertyValue
182 Nf506763ecba04f4f88e70c4d57dece29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Middle Aged
184 rdf:type schema:DefinedTerm
185 Nfe586bd192224ba6bfc2411a14ad1c12 schema:name Quantitative Solutions Inc., 94025, Menlo Park, CA, USA
186 rdf:type schema:Organization
187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
188 schema:name Medical and Health Sciences
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
191 schema:name Clinical Sciences
192 rdf:type schema:DefinedTerm
193 sg:journal.1088364 schema:issn 0344-5704
194 1432-0843
195 schema:name Cancer Chemotherapy and Pharmacology
196 rdf:type schema:Periodical
197 sg:person.01034251740.93 schema:affiliation N49fec7a46a564634a35e1e898f180830
198 schema:familyName Li
199 schema:givenName Hanbin
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034251740.93
201 rdf:type schema:Person
202 sg:person.01156553111.63 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
203 schema:familyName Garg
204 schema:givenName Amit
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156553111.63
206 rdf:type schema:Person
207 sg:person.01246121610.06 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
208 schema:familyName Visich
209 schema:givenName Jennifer
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246121610.06
211 rdf:type schema:Person
212 sg:person.01274422554.44 schema:affiliation Nfe586bd192224ba6bfc2411a14ad1c12
213 schema:familyName Wada
214 schema:givenName D. Russell
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274422554.44
216 rdf:type schema:Person
217 sg:person.01320560307.61 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
218 schema:familyName Quartino
219 schema:givenName Angelica
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320560307.61
221 rdf:type schema:Person
222 sg:person.013666353540.75 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
223 schema:familyName Li
224 schema:givenName Jing
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013666353540.75
226 rdf:type schema:Person
227 sg:person.015330562112.33 schema:affiliation https://www.grid.ac/institutes/grid.411083.f
228 schema:familyName Cortés
229 schema:givenName Javier
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015330562112.33
231 rdf:type schema:Person
232 sg:person.016026247332.04 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
233 schema:familyName Jin
234 schema:givenName Jin
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016026247332.04
236 rdf:type schema:Person
237 sg:person.0630377443.79 schema:affiliation N4cafb4e73cd24b10b5bc82e6418174dc
238 schema:familyName Ross
239 schema:givenName Graham
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630377443.79
241 rdf:type schema:Person
242 sg:person.0716757142.45 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
243 schema:familyName Lum
244 schema:givenName Bert
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716757142.45
246 rdf:type schema:Person
247 sg:person.0740256140.14 schema:affiliation Nadd324ad84f840e2b24200823b73518f
248 schema:familyName McNally
249 schema:givenName Virginia
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740256140.14
251 rdf:type schema:Person
252 sg:pub.10.1007/bf01061469 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000869925
253 https://doi.org/10.1007/bf01061469
254 rdf:type schema:CreativeWork
255 sg:pub.10.1007/s00280-005-1026-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1034184349
256 https://doi.org/10.1007/s00280-005-1026-z
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/s11095-006-0205-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1053700895
259 https://doi.org/10.1007/s11095-006-0205-x
260 rdf:type schema:CreativeWork
261 sg:pub.10.1038/nature01392 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044473219
262 https://doi.org/10.1038/nature01392
263 rdf:type schema:CreativeWork
264 sg:pub.10.1038/sj.bjc.6604043 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033972314
265 https://doi.org/10.1038/sj.bjc.6604043
266 rdf:type schema:CreativeWork
267 sg:pub.10.1186/bcr2891 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048134520
268 https://doi.org/10.1186/bcr2891
269 rdf:type schema:CreativeWork
270 sg:pub.10.1208/s12248-009-9133-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046129728
271 https://doi.org/10.1208/s12248-009-9133-0
272 rdf:type schema:CreativeWork
273 sg:pub.10.2165/11531280-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033453107
274 https://doi.org/10.2165/11531280-000000000-00000
275 rdf:type schema:CreativeWork
276 sg:pub.10.2165/11596370-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002877462
277 https://doi.org/10.2165/11596370-000000000-00000
278 rdf:type schema:CreativeWork
279 https://app.dimensions.ai/details/publication/pub.1077362565 schema:CreativeWork
280 https://doi.org/10.1016/j.ccr.2009.03.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048708034
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1016/j.clim.2006.09.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002784837
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1016/j.cllc.2012.03.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003176650
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1016/s1470-2045(11)70336-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006777850
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1016/s1470-2045(13)70130-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1014610655
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1016/s1535-6108(02)00097-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009224253
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1016/s1535-6108(04)00083-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002635571
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1056/nejmoa1113216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013126608
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1093/annonc/mds282 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052126620
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1093/annonc/mdt182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049729330
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1093/annonc/mdt201.21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000974569
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1093/jjco/hyp006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008373070
303 rdf:type schema:CreativeWork
304 https://doi.org/10.1097/cad.0000000000000016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030996000
305 rdf:type schema:CreativeWork
306 https://doi.org/10.1152/ajpgi.00286.2005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046893737
307 rdf:type schema:CreativeWork
308 https://doi.org/10.1158/0008-5472.can-08-4597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053676255
309 rdf:type schema:CreativeWork
310 https://doi.org/10.1158/1078-0432.ccr-07-0460 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050562687
311 rdf:type schema:CreativeWork
312 https://doi.org/10.1158/1078-0432.ccr-07-1980 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048629373
313 rdf:type schema:CreativeWork
314 https://doi.org/10.1158/1078-0432.ccr-07-4636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010128696
315 rdf:type schema:CreativeWork
316 https://doi.org/10.1177/0091270009337512 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002934176
317 rdf:type schema:CreativeWork
318 https://doi.org/10.1177/0091270009339192 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053425807
319 rdf:type schema:CreativeWork
320 https://doi.org/10.1200/jco.2005.03.184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003642271
321 rdf:type schema:CreativeWork
322 https://doi.org/10.1200/jco.2005.05.4221 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019457020
323 rdf:type schema:CreativeWork
324 https://doi.org/10.1200/jco.2006.07.0649 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042521222
325 rdf:type schema:CreativeWork
326 https://doi.org/10.1200/jco.2006.07.0888 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017055849
327 rdf:type schema:CreativeWork
328 https://doi.org/10.1200/jco.2009.22.3354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009371322
329 rdf:type schema:CreativeWork
330 https://doi.org/10.1200/jco.2009.24.1661 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028339567
331 rdf:type schema:CreativeWork
332 https://doi.org/10.1200/jco.2009.24.2024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001727306
333 rdf:type schema:CreativeWork
334 https://doi.org/10.1200/jco.2011.37.4207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019059111
335 rdf:type schema:CreativeWork
336 https://doi.org/10.5414/cpp48297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072835721
337 rdf:type schema:CreativeWork
338 https://www.grid.ac/institutes/grid.411083.f schema:alternateName Hospital Universitari Vall d'Hebron
339 schema:name Department of Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
340 rdf:type schema:Organization
341 https://www.grid.ac/institutes/grid.418158.1 schema:alternateName Roche (United States)
342 schema:name Clinical Pharmacology, MS 463a, Genentech, Inc., 1 DNA Way, 94080, South San Francisco, CA, USA
343 MedImmune, 24500 Clawiter Road, 94545, Hayward, CA, USA
344 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...